Disseminated Mycobacterium avium complex disease is the most common bacterial opportunistic infection of persons with AIDS and is occurring more frequently among such patients as the AIDS epidemic matures [1] ; in 1992 an estimated 15,000-24,000 persons with AIDS acquired M. avium complex disease in the United States alone [2] . The disease causes substantial morbidity among persons with AIDS and is associated with shortened survival [1] [2] [3] [4] [5] . Moreover, prevention and treatment of M. avium complex disease are only partially effective [6] .
M. avium complex disease occurs in 20%-25% of patients with AIDS; all age, sex, race, and HIV risk groups are affected [l, 7] . The only risk factors for the disease that have been identified are the level of the CD4 lymphocyte count and prior occurrence of an AIDS-indicating condition [8, 9] . Moreover, the risk for M avium complex disease rises as the CD4 cell count declines [8] , prompting some investigators to speculate that disease frequency would approach 100% if patients survived longer. However, natural history studies have shown that, even at the lowest CD4 cellleve1s, many persons do not acquire this disease [3, 5, 8, 10] . Such protection might be explained by lack of exposure to the pathogen, but M avium complex organisms are ubiquitous [1] , and epidemiologic studies to define environmental risk factors have been unrevealing [11, 12] .
We investigated the possibility that some persons may have immune mechanisms that protect them from acquiring M avium complex disease despite frequent exposure. Such protection might be expected in persons with a positive tuberculin skin test or a history oftuberculosis for several reasons. First, skin test reactivity to purified protein derivative (PPD) identifies persons who have a decreased risk of developing tuberculosis disease following exposure to Mycobacterium tuberculosis [13, 14] . Second, increases in pulmonary M avium complex disease in persons without AIDS at a time when tuberculosis was waning suggest that protection against M avium complex by M tuberculosis infection or disease may have been present previously [15] . Third, AIDS patients from areas of the world where tuberculosis is common, such as Africa, have a marked reduction in the frequency of M avium complex disease [16, 17] .
Therefore, we did a retrospective study to define the risk of M. avium complex disease in persons with human immunodeficiency virus (HIV) infection and a history of tuberculosis or a positive PPD skin test and compared this risk to that of persons with similar CD4 lymphocyte counts but without a history of tuberculosis or a positive PPD skin test. We then confirmed these results by examination of the risk factors for M. avium complex disease in patients in a larger multicenter study of the natural history of HIV infection done in collaboration with the Centers for Disease Control and Prevention (CDC). enrolled in the Infectious Diseases Clinic between 1 January 1985 and 31 December 1993, as described previously [18] . Data included demographics, opportunistic infections and conditions included in the 1987 AIDS case definition, PPD and anergy skin test status, history of tuberculosis, use of antiretroviral and antimycobacterial agents, all available CD4 cell counts, and survival status. M. avium complex disease was defined as a blood culture positive for M. avium. A positive PPD skin test was defined as a reaction of~5 mm, as recommended by the CDC [19] . In the analysis of the effect of PPD skin test status, persons who were not PPD-tested or who were anergic were excluded. In the analysis of the effect of tuberculous disease, the 8-month period after the initial culture was positive for M. tuberculosis was excluded to eliminate potential confounding by therapy for tuberculosis.
Adult and Adolescent Spectrum of HIV Disease (ASD) Project.
The ASD Project is conducted in US cities to supplement national AIDS reporting and includes > 100 selected medical facilities that provide outpatient or inpatient HIV care or both. This report includes information from Dallas, Denver, Detroit, Houston, Los Angeles, New Orleans, San Antonio (TX), Seattle, and Bayamon, Puerto Rico. Observation of HIV-infected persons~13 years old begins at the time of their first visit or hospital admission, regardless of the number of previous health care visits or stage of HIV disease. A complete history of diagnoses of opportunistic infections and conditions included in the 1987 AIDS case definition is obtained. Enrollment procedures and data collection methods have been described [20] . Since pulmonary tuberculosis without dissemination was not part of the 1987 AIDS case definition, some persons with tuberculosis prior to 1989 (or 1 year before enrollment) may not have been identified. In this report, data collected from January 1990 through August 1995 were analyzed; data from patients in Georgia were excluded to avoid potential overlap with the GMH cohort. Therapy for tuberculosis was defined as administration of at least isoniazid (INH) plus rifampin or rifamate. Duration of therapy was included for patients receiving INH and rifampin for suspected tuberculosis (for brief periods while culture results were pending) and for confirmed cases of tuberculosis. Antiretroviral therapy was defined as administration of zidovudine, didanosine, zalcitabine, or stavudine, alone or in combination.
Statistical methods. Comparisons of demographic characteris-
tics between dichotomous variables were made using X 2 tests. Continuous variables were compared using the Wilcoxon rank sum test. To assess the relationship between a positive tuberculin skin test or a history of active tuberculosis and subsequent M. avium complex disease in the GMH cohort, we performed Kaplan-Meier analyses, beginning with the first CD4 cell count <200/mm 3 • For persons with tuberculosis, the first such count after completion of antituberculosis therapy was used. Tests of significance were done using the log-rank test.
To clarify the relationship between prior tuberculosis and risk for subsequent M. avium complex disease and control for potential confounders for tuberculosis and the effects of known predictors of M. avium complex disease, we did multivariate proportional hazards regression using both the ASD and GMH cohorts. In the model using ASD data, persons who died within 8 months of the diagnosis of tuberculosis were excluded, since they were likely to be receiving antituberculous therapy for the entire follow-up period. Opportunistic infections, treatment with antituberculous agents, M. avium complex prophylaxis with rifabutin, and antiretroviral therapy were modeled as time-dependent covariates. C. During 1985 During -1993 During , 1367 persons with AIDS or HIV infection and <200 CD4 cells/mrrr' were seen at the Infectious Diseases Clinic of GMH. Of these, 66 had a positive PPD skin test; 185 had a negative PPD skin test but were not anergic. Median survival of the PPD-positive group was 18 months, while that of the PPDnegative group was 22 months (P = 040). PPD-positive persons were more likely than PPD-negative, nonanergic persons to be nonwhite (56/66 vs. 130/185, P = .02) or intravenous drug users (34/66 vs. 46/185, P < .01), but initial CD4 cell counts were not significantly different between the groups (115 cells/ mnr' for PPD-positive vs. 95 cells/mrrr' for PPD-negative persons; P = 043). There were no differences in occurrence of M. avium complex disease between the PPD-positive and -negative groups (P = 044; figure I).
Results
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Effect ofprior tuberculosis on subsequent M. avium complex disease: ASD cohort. A total of 9113 HIV-infected persons enrolled in the ASD project had at least one 6-month followup after a CD4 cell count of <200 cells/mnr' and were included in the analysis. Of these, 441 had a history of tuberculosis, while 8702 were not known to have had tuberculosis; overall, 1445 (15.9%) of the 9113 patients were diagnosed with M avium complex disease. Persons with a history of tuberculosis were more likely to be nonwhite (3011411 vs. 4553/8702; P < .001) or intravenous drug users (102/411 vs. 1120/8702; P < .001). Survival times of patients with and without a history of tuberculosis were similar (20 months vs. 22 months; P = .33). In patients with a history of tuberculosis who had initial CD4 cell counts of 100-199 cells/mrrr', tuberculosis had been diagnosed a median of 6 months prior to occurrence of the first CD4 cell count <200 cells/rum"; in patients with tuberculosis who had initial CD4 cell counts of 0-99 cells/mrrr', tuberculosis had been diagnosed a median of 4 months prior to occurrence of the first CD4 cell count < 100 cells/rum'.
The proportional hazards regression model of risk factors for M. avium complex in these patients is shown in table 2. In multivariate analysis, protection was significantly associated with higher CD4 cell count, rifabutin prophylaxis, history of tuberculosis, antiretroviral therapy, nonwhite race, and intravenous drug use; occurrence of an opportunistic infection other than tuberculosis was significantly associated with increased risk of M. avium complex disease. When the patients were stratified by level of the first CD4 cell count <200/rnm 3 , pa- tients with a history of tuberculosis whose initial CD4 cell count was 100-I99/mm 3 had greater protection against M avium complex (relative risk, 0.33; 95% confidence interval, 0.12-0.94) than patients with a history of tuberculosis whose initial CD4 cell count was 0-99 CD4 cells/mrrr' (relative risk, 0.57; 95% confidence interval, 0.38-0.86).
Discussion
This study demonstrates protection against M avium complex disease in HIV-infected persons with a history oftuberculosis. Such protection was significant in both the Atlanta clinic and the national database. Moreover, protection remained after controlling for factors known to influence the risk for M. avium complex disease, such as CD4 lymphocyte count, occurrence of other AIDS-indicating conditions, and rifabutin prophylaxis [21] . While some persons in the ASD cohort may have been incorrectly classified as not having had tuberculosis if it occurred prior to 1989 or 1 year before enrollment, such misclassification would only diminish the observed effect; thus, protection may be greater than observed. These observations are consistent with the hypothesis that protection afforded by prior exposure to M tuberculosis accounts for the low rates of M avium disease in African patients with AIDS [17, 22] .
M. avium complex disease is thought to be the result of recent environmental exposure to the organism [1, 11, 12, 22] ; reactivation of previously acquired M. avium disease has not been documented, and the incidence of M. avium disease in patients with AIDS is substantially greater than would be predicted by the prevalence of positive M avium skin tests [22] . Nonetheless, the protection against M. avium complex disease afforded by previous tuberculosis could be explained by administration of antituberculous medications for therapy of tuberculosis, since two of the four most commonly used antituberculous agents, rifampin and ethambutol, have modest in vitro activity against M. avium complex [6] . We believe this is an unlikely explanation for the observed protection, since such therapy was not associated with significant protection against M. avium complex disease in persons in the ASD cohort receiving antituberculous therapy during this analysis (table 2) . Moreover, protection against M. avium complex disease by rifabutin does not persist after the drug is discontinued (Schoenfelder J, personal communication), indicating that antimycobacterial prophylaxis provides protection by treating recurrent exposures rather than by eliminating latent foci of M. avium infection. Since the duration of therapy for tuberculosis was controlled for in the analyses presented, it does not explain the observed protection.
A more likely mechanism for protection from M. avium complex disease in persons with a history of tuberculosis is acquired immunity against mycobacteria. Such acquired immunity has previously been observed in humans, in whom previous tuberculosis provided protection against subsequent exposure to M. tuberculosis [12, 13] , and in animals, in which guinea pigs and rabbits that had had tuberculosis were protected against subsequent exposure [23, 24] . Infection with bacille CalmetteGuerin (BCG), an attenuated strain of Mycobacterium bovis, also protects humans and animals against both tuberculosis and nontuberculous mycobacterial infection [25] [26] [27] [28] [29] [30] [31] [32] , and one report has proposed that this protection may extend to patients with AIDS [33] . Our observation that protection against M. avium complex disease was greater in persons with a history of tuberculosis who were observed beginning at higher CD4 cell levels is consistent with a conclusion that immune mechanisms are involved, since persons with lower CD4 cell counts would be expected to have decreased protective immunity.
Protection was not seen, however, in persons with a history of a positive PPD skin test without a history of active disease. OUf inability to demonstrate protection against M. avium complex disease in such persons may be due to several factors. First, tuberculosis disease may provide more persistent immune stimulation than does tuberculosis infection and, thus, greater immunity. Second, INH prophylaxis, given routinely to patients in our clinic, may decrease immune stimulation by persistent tubercle bacilli; PPD-positive persons who do not receive INH (such as those in Africa) may therefore have protection that could not be observed in the present study. Third, skin test lID 1996; 174 (December) results are known to be an inexact marker for protective immunity to mycobacterial infection [34] . Thus, some persons classified in this study as having tuberculous infection might not have had protective immunity. Fourth, because a 5-mm reaction was used to define a positive test, some persons identified as infected by mycobacteria may instead have only been sensitized to environmental mycobacteria.
This study confirms previous reports that the level of the CD4 lymphocyte count and the occurrence of an opportunistic infection are independent risk factors for M avium complex disease in HIV -infected persons and that rifabutin prophylaxis is protective (too few persons in our cohort received other antimycobacterial prophylactic regimens to permit analysis of such protection). We also identified protection againstM. avium complex disease by antiretroviral therapy. While the mechanism for such protection is not known, it is likely that such therapy reduces the risk of M. avium complex disease by retarding CD4 cell decline or by enhancing other immunologic defenses against M. avium complex.
Protection against M. avium complex disease was also seen in the ASD cohort in nonwhite patients and in intravenous drug users. Previous analysis of these factors had not shown them to protect against M. avium complex disease, but that report concerned the period 1981-1987 [7] . The emergence of these factors as protective against M. avium complex disease could indicate biologic or behavioral differences in exposure or susceptibility to M. avium complex that have occurred since 1987. However, the only previously identified racial differences would suggest increased rather than decreased susceptibility to mycobacterial disease in nonwhites [35] . A more likely explanation for the observed protection is that some prior episodes oftuberculosis in patients in the ASD cohort were not reported; such unreported cases would preferentially have occurred in nonwhites and intravenous drug users, groups known to be at increased risk for tuberculosis. As noted in the methods, such unreported cases were likely, since cases of tuberculosis that occurred before 1989 were not recorded. Protection from M. avium complex disease afforded by those unreported cases of tuberculosis would appear as decreased risk for M avium complex disease attributable to nonwhite race and intravenous drug use. Such a conclusion is supported by our failure to observe protection from M. avium complex by nonwhite race or intravenous drug use in the GMH cohort, for whom information about tuberculosis was more complete.
This study was limited by several factors. First, information on PPD skin test status was incomplete for many members of the GMH cohort and not collected in the ASD study. Thus, protection afforded by infection with M. tuberculosis without disease may not have been detected. Second, our analyses were limited to patients who were being seen in a health care setting and may not accurately represent outcomes of patients without access to such care. Third, since patients were not screened prospectively for the occurrence of M. avium disease, not all cases may have been detected at some centers in the ASD cohort; however, after controlling for other factors, rates of M avium complex disease did not differ between the sites (data not shown). While such underdetection may have occurred, it is likely to have occurred equally in persons with and without a history of tuberculosis. The overall rates of M avium disease would thereby have been decreased, thus underestimating the true protective effect.
The number of patients with AIDS is substantial, and existing efforts to prevent M. avium complex disease, such as antibiotic prophylaxis regimens, are expensive, potentially toxic, and offer incomplete protection. Decreased risk of M. avium complex disease in HIV-infected persons with a history of tuberculosis suggests that even patients with very low CD4 cell counts can maintain immunologic protection against M avium complex disease. Studies are needed to confirm these observations and define the mechanisms that underlie this protection. If immune mechanisms are responsible, efforts to develop vaccines that can confer immunity will be warranted. While BCG vaccination might provide such immunity, its use is limited in HIV -infected persons because of the risk of disseminated BCG infection. Killed mycobacterial vaccines might provide a safe alternative; this area of research was a promising one in the 1950s [36, 37] but has only attracted a small number of investigators since that time [38] .
